Patent · US Expired

Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice

US6455756B1 · kind B1 · utility

23Cited by
1References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 12, 1994
Grant dateSep 24, 2002
Priority date—
Expiry dateAug 12, 2014

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA01K67/0271
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Immunocompromised mammalian hosts are sub-cutaneously implanted with a combination of human fetal bone and spleen. The chimeric animals can produce human B-cells, myeloid cells and T-cells for up to 9 months in vivo when supplied with an allogeneic human fetal thymic fragment at the same site. Grafts contain cell populations expressing CD4 and CD8, CD19 or CD33, CD14 and CD15, all of which also express the HLA type of the fetal bone/spleen. T-cells derived from progenitors in the fetal bone/spleen contain both mature single positive CD4+CD8−, CD8+CD4− as well as a high percentage of immature double positive CD4+CD8+ populations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.